AstraZeneca Concentrates On Collaborations In China
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca may not be China's number one MNC pharmaceutical in sales, but its prescription drug revenue has consistently topped the chart for years. This success stems from the various strategies adopted by AstraZeneca China over the past three years that emphasized collaboration. In 2006, the firm dismantled its OTC sales team and worked with local distribution channels to push its drugs. It also pioneered being the first MNC agent representing other companies' pharmaceutical products in China. In the process, the corporation helps to raise domestic enterprises' profile in the worldwide value chain as well as introduce many key global products into China. Drugs brought in include those against major diseases listed in the local medical insurance catalog and products with big potential market. (Click here for more - Chinese Language)